# Boston Scientific: how the business works

> For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Boston Scientific Corporation · NYSE: BSX · Sector: Health Care

Updated for Q3 FY2026 · checked Nov 20, 2026

This is the plain-text version of https://cityfort.co/stocks/boston-scientific. Source ids in [brackets] refer to the list at the end. Credit: "Cityfort, Boston Scientific: how the business works", with the page URL.

## The 30-second summary

Boston Scientific makes devices that doctors use inside the body, such as heart ablation catheters, the Watchman implant and stents, and had $20.1 billion of net sales in FY2025. Hospitals and buying groups pay for them, and the company kept $14.3 of every $100 that came in as net income. In August 2026 a cyber incident disrupted shipping. Its FY2026 sales growth estimate went from 10.5% to 11.5% in February to about 4.25% on Oct 28, after cuts in April and July.

## 5 points

- **What it sells:** Boston Scientific makes medical devices that doctors use inside the body, mostly through a catheter or a scope, and had net sales of $20.1 billion in FY2025 across eight businesses. [S4]
- **Who pays it:** Hospitals and other buyers in the United States paid 64.1% of FY2025 net sales, while buyers in Europe, the Middle East and Africa paid 17.2%, Asia-Pacific 15.3% and Latin America and Canada 3.4%. [S4]
- **What it keeps from $100:** Of every $100 that came in during FY2025, Boston Scientific kept $14.3 as net income; its operating income, before interest and tax, was 18.0% of sales. [S4]
- **Where the operating profit comes from:** In FY2025 the Cardiovascular segment earned $4.30 billion of segment operating income before corporate costs and amortization, against $2.27 billion for MedSurg. [S4]
- **The one thing to watch:** Boston Scientific's Oct 28, 2026 release estimates FY2026 net sales growth of about 4.25%, down from the 10.5% to 11.5% it estimated on Feb 4, 2026. [S16, S19]

## What does Boston Scientific sell?

Boston Scientific makes medical devices that doctors use inside the body, mostly through a thin tube (catheter) or a scope instead of open surgery. It sold $20.1 billion of them in FY2025 across eight businesses.

- **Interventional Cardiology and Vascular Therapies ($4.64 billion, FY2025):** Catheters, balloons, stents and imaging tools that open blocked heart and leg arteries, such as AVVIGO+ imaging and Bolt Medical lithotripsy, which breaks up hard deposits. [S4]
- **Electrophysiology ($3.33 billion):** Tools that treat an irregular heartbeat (atrial fibrillation) by ablation, led by the FARAPULSE pulsed field ablation system launched in the US in 2024, plus OPAL HDx heart mapping. [S4, S8]
- **Cardiac Rhythm Management ($2.33 billion):** Pacemakers and defibrillators, including the EMBLEM S-ICD placed under the skin, and HeartLogic heart-failure alerts. [S4]
- **Watchman ($1.96 billion):** An implant that closes a small pouch of the heart, the left atrial appendage, in people with atrial fibrillation at risk of stroke who can take blood thinners. [S4]
- **Interventional Oncology and Embolization ($996 million):** TheraSphere radioactive glass beads for liver tumors and coils such as EMBOLD that block blood vessels. [S4]
- **Endoscopy ($2.92 billion):** Devices used through a scope in the digestive tract, such as Resolution 360 and MANTIS clips and WallFlex and AXIOS stents. [S4]
- **Urology ($2.71 billion):** Kidney stone tools (LithoVue scopes, Lumenis Pulse lasers), the GreenLight XPS prostate laser and Axonics bladder and bowel nerve stimulators. [S4]
- **Neuromodulation ($1.20 billion):** WaveWriter Alpha spinal cord stimulators for chronic pain, Intracept for low back pain and Vercise deep brain stimulation. [S4]

## Who pays Boston Scientific?

- **Hospitals, clinics and medical offices:** Hospitals, clinics, outpatient facilities and medical offices in 127 countries buy the devices that their doctors use in procedures. [S4]
- **Buying groups and hospital networks:** Large group purchasing organizations, hospital networks and other buying groups negotiate for many hospitals; the FY2025 10-K says they represent a substantial portion of net sales. [S4]
- **Distributors and dealers:** In countries without a Boston Scientific sales force, distributors and dealers buy and resell the products. [S4]
- **Insurers and governments (indirectly):** Hospitals and doctors usually bill insurers and government health programs for procedures, so their payment rules affect demand for the devices. [S4]
- **Customer concentration:** No single customer was more than 10% of net sales in 2025, 2024 or 2023, the FY2025 10-K says. US customers bought 64.1% of FY2025 net sales (Cityfort calculation from the FY2025 10-K). [S4]

## Where the money went (FY2025)

1. Hospitals, clinics and other buyers paid Boston Scientific $20.1 billion of net sales in FY2025, and other income added $121 million.
2. Making the products cost $6.2 billion, leaving $13.9 billion of gross profit, or $69.0 of every $100 of sales.
3. Sales teams and administration took $6.9 billion and research and development $2.1 billion.
4. Amortization of acquired intangibles, impairments, restructuring, litigation and other charges took $1.3 billion, leaving $3.6 billion of operating income.
5. Interest cost $349 million and income tax $493 million, and $2.9 billion was left as net income.

Sources: S4.

## Key numbers by year (US$ million)

Financials: consolidated, US$ million. Fiscal years are the company's own: December 31 (the fiscal year is the calendar year, so Q3 FY2026 is July to September 2026). — = not shown on the page.

| Year | Revenue | EBITDA | EBITDA margin | Net profit | Net margin | EPS (US$ per share, diluted) | Operating cash flow | Capital spending | Free cash flow | Sources |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FY2021 | 11,888 | 2,292 | 19.3% | 985 | 8.3% | 0.69 | 1,870 | 554 | 1,316 | S14, S12 |
| FY2022 | 12,682 | 2,785 | 22.0% | 642 | 5.1% | 0.45 | 1,526 | 588 | 938 | S13, S12 |
| FY2023 | 14,240 | 3,539 | 24.9% | 1,570 | 11.0% | 1.07 | 2,503 | 711 | 1,792 | S12 |
| FY2024 | 16,747 | 3,872 | 23.1% | 1,853 | 11.1% | 1.25 | 3,435 | 790 | 2,645 | S8, S4 |
| FY2025 | 20,074 | 4,981 | 24.8% | 2,898 | 14.4% | 1.94 | 4,534 | 876 | 3,658 | S4 |

- EBITDA here = operating income plus depreciation and amortization (from the cash flow statement).
- Net profit is the share belonging to the company's owners.
- FY2025: Net income attributable to common stockholders excludes the $6 million of losses attributable to noncontrolling interests; total net income was $2,892 million.

## Balance sheet (as of Sep 30, 2026, US$ million)

Net debt was $11.3 billion at Sep 30, 2026, about 2.3 times FY2025 EBITDA of $5.0 billion (Cityfort calculation from the FY2025 10-K and the Q3 FY2026 10-Q). [S1, S4]

| Item | Value |
| --- | --- |
| Total debt | 11,953 |
| Cash and investments | 609 |
| Net debt (debt minus cash) | 11,344 |
| Net worth (shareholders' money) | 25,630 |
| Debt to equity (times) | 0.47 |

- Net debt is total debt of $11.95 billion (current $1.04 billion plus long-term $10.91 billion) minus $609 million of cash (Cityfort calculation from the Q3 FY2026 10-Q). At Dec 31, 2025 it was $9.47 billion (Cityfort calculation from the FY2025 10-K).
- The leverage ratio under the credit agreements was 1.95 times at Sep 30, 2026, against a maximum of 3.75 times, the 10-Q says; the maximum can rise to 4.75 times for four quarters after a qualifying acquisition.
- A $6.0 billion term loan agreement signed Feb 26, 2026 can be drawn only when the Penumbra acquisition closes.
- Cash fell from $1.97 billion at Dec 31, 2025 to $609 million at Sep 30, 2026; in between, the company paid $2.0 billion for an accelerated share repurchase, and other investments rose from $681 million to $2.29 billion.
- Goodwill and other intangible assets were $25.6 billion, or 56.3% of total assets of $45.5 billion at Sep 30, 2026 (Cityfort calculation from the Q3 FY2026 10-Q).

## Who owns Boston Scientific? (as of Mar 6, 2026)

Boston Scientific has one class of common stock with one vote per share. Directors and executive officers as a group (18 people) held 4,999,093 shares on Mar 6, 2026, which the proxy marks as under 1%; 0.3% is a Cityfort calculation from the 2026 proxy statement. Percentages use the March 2026 share count, before the May 2026 buyback; the rows have different dates and are not added together. [S15, S1]

- Officers and directors (as a group), shares: 0.3%

| Class | Shares (millions) | Votes per share | % of shares | % of votes | Traded | Sources |
| --- | --- | --- | --- | --- | --- | --- |
| Common stock (1,449,473,222 shares at Oct 29, 2026 (Q3 FY2026 10-Q cover), down from 1,486,175,167 at Mar 6, 2026 (2026 proxy). It is the only class; no preferred shares were issued at Sep 30, 2026.) | 1,449.47 | 1 | — | — | Yes | S1, S15 |

Holders of 5% or more (each row shows the date of its own filing):

| Holder | Shares | Votes | As of | Note | Sources |
| --- | --- | --- | --- | --- | --- |
| The Vanguard Group | 8.44% | — | Feb 13, 2024 | 125,449,595 shares, as listed in the 2026 proxy from a Schedule 13G/A filed Feb 13, 2024. | S15 |
| BlackRock, Inc. | 7.6% | — | Apr 17, 2025 | 113,006,671 shares, as listed in the 2026 proxy from a Schedule 13G/A filed Apr 17, 2025. | S15 |
| FMR LLC (Fidelity) | 7.42% | — | Aug 6, 2025 | 110,320,938 shares, as listed in the 2026 proxy from a Schedule 13G/A filed Aug 6, 2025. | S15 |

## What could go wrong

### Recovery from the August 2026 cyber incident

The incident disrupted manufacturing, order processing and shipping and materially impacted Q3 FY2026, the 10-Q says. Q3 net sales grew 1.5% against the company's estimate of 3% to 5%. [S1, S16, S17]

What to watch: Q4 FY2026 net sales against the company's estimate of a 1.0% to 3.0% fall

### More competition in Electrophysiology

Electrophysiology grew from $800 million in FY2023 to $3.33 billion in FY2025, and the Q3 FY2026 10-Q cites increased competition in 2026. [S4, S1]

What to watch: Electrophysiology sales in the FY2026 10-K

### Slower left atrial appendage closure market

The Q3 FY2026 10-Q says a deceleration in this market affected Watchman procedures in 2026. Watchman was $1.96 billion, 9.8% of FY2025 net sales. [S1, S4]

What to watch: Watchman sales in FY2026 against $1,958 million in FY2025

### Penumbra deal and more debt

The Penumbra purchase, about $14.5 billion, awaits FTC review; the company said in its Q3 FY2026 10-Q (Nov 2, 2026) that it expects completion in early 2027. A $6.0 billion term loan can be drawn at closing, on top of $11.95 billion of debt at Sep 30, 2026. [S1]

What to watch: The FTC outcome, and total debt and the leverage ratio after closing

### Lawsuits and legal charges

Litigation-related net charges were $157 million in the first nine months of 2026, against none a year earlier, and the legal accrual rose to $370 million. Cases include spinal cord stimulator and surgical mesh product liability claims and a securities class action alleging misleading statements. [S1]

What to watch: Litigation-related charges and the legal accrual in each 10-Q and 10-K

### Price pressure from buyers and governments

The FY2025 10-K says buying groups, governments and insurers push to contain health care costs. The Q3 FY2026 10-Q names volume-based procurement in China, where the government buys at set prices, as a reason for the Endoscopy and Urology declines. [S4, S1, S16]

What to watch: Asia-Pacific sales growth, which was -0.6% in Q3 FY2026

### Tax incentives that expire

The Costa Rica plants operate under a Free Trade Zone regime, and the company benefits from tax holidays elsewhere; the FY2025 10-K says these benefits end unless extended. [S4]

What to watch: The effective tax rate in each 10-K

## What to watch

Next: Q4 FY2026 results, Date not announced yet.

- **Q4 FY2026 net sales:** In its Oct 28, 2026 release the company said it expects Q4 FY2026 net sales to fall 1.0% to 3.0%; the Q4 results will show the actual figure.
- **Penumbra purchase:** The roughly $14.5 billion deal awaits FTC review; the company said in its Q3 FY2026 10-Q (Nov 2, 2026) that it expects completion in early 2027.
- **Electrophysiology and Watchman sales:** Electrophysiology had $3.33 billion and Watchman $1.96 billion of FY2025 net sales; the Q3 FY2026 10-Q cites more competition and a slower market in 2026.

## Sources

- S1: Form 10-Q for Q3 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/885725/000088572526000070/0000885725-26-000070-index.htm (published Nov 2, 2026)
- S2: Form 10-Q for Q2 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/885725/000088572526000053/0000885725-26-000053-index.htm (published Aug 3, 2026)
- S3: Form 10-Q for Q1 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/885725/000088572526000033/0000885725-26-000033-index.htm (published May 1, 2026)
- S4: Form 10-K for FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/0000885725-26-000010-index.htm (published Feb 17, 2026)
- S5: Form 10-Q for Q3 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/885725/000088572525000050/0000885725-25-000050-index.htm (published Nov 3, 2025)
- S6: Form 10-Q for Q2 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/885725/000088572525000041/0000885725-25-000041-index.htm (published Aug 1, 2025)
- S7: Form 10-Q for Q1 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/885725/000088572525000026/0000885725-25-000026-index.htm (published May 1, 2025)
- S8: Form 10-K for FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/885725/000088572525000011/0000885725-25-000011-index.htm (published Feb 18, 2025)
- S9: Form 10-Q for Q3 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/885725/000088572524000073/0000885725-24-000073-index.htm (published Nov 1, 2024)
- S10: Form 10-Q for Q2 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/885725/000088572524000068/0000885725-24-000068-index.htm (published Aug 1, 2024)
- S11: Form 10-Q for Q1 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/885725/000088572524000046/0000885725-24-000046-index.htm (published May 1, 2024)
- S12: Form 10-K for FY2023. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/885725/000088572524000017/0000885725-24-000017-index.htm (published Feb 20, 2024)
- S13: Form 10-K for FY2022. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/885725/000088572523000008/0000885725-23-000008-index.htm (published Feb 23, 2023)
- S14: Form 10-K for FY2021. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/885725/000088572522000006/0000885725-22-000006-index.htm (published Feb 23, 2022)
- S15: 2026 proxy statement (DEF 14A). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/885725/000088572526000025/bsx-20260318.htm (published Mar 18, 2026)
- S16: Q3 FY2026 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/885725/000088572526000066/earningsrelease_live.htm (published Oct 28, 2026)
- S17: Q2 FY2026 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/885725/000088572526000051/q22026earningsrelease.htm (published Jul 29, 2026)
- S18: Q1 FY2026 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/885725/000088572526000031/q12026earningsrelease.htm (published Apr 22, 2026)
- S19: Q4 FY2025 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/885725/000088572526000006/q42025earningsrelease.htm (published Feb 4, 2026)
- S20: Q3 FY2025 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/885725/000088572525000046/q32025earningsrelease.htm (published Oct 22, 2025)
- S21: Q2 FY2025 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/885725/000088572525000039/q22025earningsrelease.htm (published Jul 23, 2025)
- S22: Q1 FY2025 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/885725/000088572525000023/q12025earningsrelease.htm (published Apr 23, 2025)
- S23: Q4 FY2024 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/885725/000088572525000007/q42024earningsrelease.htm (published Feb 5, 2025)
